PURPOSE OF REVIEW: Older adults currently represent the fastest growing demographic of cannabis users, yet few studies have investigated the effects of cannabis use on cognitive functioning in aging. We conducted a systematic review of the recent literature examining cognitive outcomes associated with cannabis use in older adults, with and without neurocognitive disorders, to clarify the potential neuroprotective benefits and risks of cognitive decline in this population. RECENT FINDINGS: We identified 26 studies examining cognitive outcomes associated with medical and recreational use of cannabis in healthy aging, dementia, Parkinson's disease, multiple sclerosis, HIV, and pain populations. Although variability in the cannabis products used, outcomes assessed, and study quality limits the conclusions that can be made, modest reductions in cognitive performance were generally detected with higher doses and heavier lifetime use. SUMMARY: This review highlights the need for additional high-quality research using standardized, validated assessments of cannabis exposure and cognitive outcomes. Reliable measures and longitudinal data are necessary to better characterize the effects of cannabis use on cognitive aging, as well as differential effects of recreational and medical cannabis.
PURPOSE OF REVIEW: Older adults currently represent the fastest growing demographic of cannabis users, yet few studies have investigated the effects of cannabis use on cognitive functioning in aging. We conducted a systematic review of the recent literature examining cognitive outcomes associated with cannabis use in older adults, with and without neurocognitive disorders, to clarify the potential neuroprotective benefits and risks of cognitive decline in this population. RECENT FINDINGS: We identified 26 studies examining cognitive outcomes associated with medical and recreational use of cannabis in healthy aging, dementia, Parkinson's disease, multiple sclerosis, HIV, and pain populations. Although variability in the cannabis products used, outcomes assessed, and study quality limits the conclusions that can be made, modest reductions in cognitive performance were generally detected with higher doses and heavier lifetime use. SUMMARY: This review highlights the need for additional high-quality research using standardized, validated assessments of cannabis exposure and cognitive outcomes. Reliable measures and longitudinal data are necessary to better characterize the effects of cannabis use on cognitive aging, as well as differential effects of recreational and medical cannabis.
Authors: Marcos Hortes N Chagas; Antonio W Zuardi; Vitor Tumas; Márcio Alexandre Pena-Pereira; Emmanuelle T Sobreira; Mateus M Bergamaschi; Antonio Carlos dos Santos; Antonio Lucio Teixeira; Jaime E C Hallak; José Alexandre S Crippa Journal: J Psychopharmacol Date: 2014-09-18 Impact factor: 4.153
Authors: Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen Journal: JAMA Date: 2015 Jun 23-30 Impact factor: 56.272
Authors: Susan Ball; Jane Vickery; Jeremy Hobart; Dave Wright; Colin Green; James Shearer; Andrew Nunn; Mayam Gomez Cano; David MacManus; David Miller; Shahrukh Mallik; John Zajicek Journal: Health Technol Assess Date: 2015-02 Impact factor: 4.014
Authors: Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook Journal: Subst Use Misuse Date: 2019-01-30 Impact factor: 2.164
Authors: Geke A H van den Elsen; Amir I A Ahmed; Robbert-Jan Verkes; Ton Feuth; Marjolein A van der Marck; Marcel G M Olde Rikkert Journal: Am J Geriatr Psychiatry Date: 2015-07-30 Impact factor: 4.105
Authors: Madeline H Meier; Avshalom Caspi; Annchen R Knodt; Wayne Hall; Antony Ambler; HonaLee Harrington; Sean Hogan; Renate M Houts; Richie Poulton; Sandhya Ramrakha; Ahmad R Hariri; Terrie E Moffitt Journal: Am J Psychiatry Date: 2022-03-08 Impact factor: 19.242
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Nina Pocuca; T Jordan Walter; Arpi Minassian; Jared W Young; Mark A Geyer; William Perry Journal: Arch Clin Neuropsychol Date: 2021-07-19 Impact factor: 2.813